We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Tuberculosis Elimination at Stake

By LabMedica International staff writers
Posted on 26 Apr 2016
Ahead of World TB Day, a new guidance paper and surveillance report on tuberculosis (TB) in Europe urge for immediate diagnostic screening and care of the most vulnerable populations, including refugees and migrants, and the poor and marginalized.

Data released in a new report by European Center for Disease Prevention and Control (ECDC; Stockholm, Sweden) and World Health Organization (WHO) show that an estimated 340,000 Europeans developed TB in 2014, corresponding to a rate of 3.7 cases per 1 million population. More...
With new TB cases decreasing by 4.3% on average between 2010 and 2014, the WHO European Region has met the Millennium Development Goal target of reversing the incidence of TB by 2015. However, high rates of multidrug-resistant (MDR) TB and TB affecting vulnerable populations (e.g., homeless, drug and alcohol abusers, and migrants from countries with high rates of TB) continue to challenge TB elimination (defined as < 1 case TB disease per 1 million population per year).

The WHO European Region comprises 53 countries with a population of nearly 900 million people, of which around 508 million live in the EU/EEA (European Union/European Economic Area: 28 EU Member States plus Iceland, Liechtenstein, and Norway).

"One quarter of all 480,000 patients sick with MDR TB globally were in the European Region in 2014. This alarmingly high number is a major challenge for TB control", said Dr. Zsuzsanna Jakab, WHO Regional Director for Europe, "The most vulnerable groups [...] are at greater risk of developing MDR TB. Because of their living conditions, TB is often diagnosed late, and it is harder for them to complete a treatment course. If we really want to eliminate TB from Europe, no one must be left behind."

"Social circumstances or lifestyles may make it more difficult for some people to recognize the symptoms of TB, access healthcare services, follow a treatment, or attend regular healthcare appointments. We need to think about tailored interventions for such vulnerable people, which can include outreach teams or directly observed treatment," said ECDC acting director Dr Andrea Ammon, “If TB is not successfully tackled in vulnerable groups, it will not be eliminated."

There is no systematic association between migration and transmission of tuberculosis. The risk of being infected or developing TB disease depends on several factors including TB rates in country of origin. New TB cases in some origin countries (e.g., Syria) are lower than the European Region average. In addition, as TB is not easily transmissible and contacts are limited, there is a low risk that migrants transmit the disease to the resident population.

Universal health coverage should be ensured for refugees and migrants, both documented and undocumented. The European Region is the only one in the world with a consensus document on the minimum package of cross-border TB control and care interventions, including access to medical services irrespective of a migrant's registration status. TB screening must never be used as a reason to reject a refugee or a migrant. The recently published Systematic screening for active tuberculosis: an operational guide provides guidance on how to target and tailor TB screening to detect active disease and provide immediate treatment in populations most at risk.

Related Links:
European Center for Disease Prevention and Control


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The new study aims to enhance colorectal cancer prevention by identifying polyp molecular signals (Photo courtesy of Shutterstock)

RNA Screening Test Could Detect Colon Polyps Before They Become Cancerous

Colorectal cancer has become a growing health crisis, especially as it increasingly affects younger adults in their 20s, 30s, and 40s, while screening rates remain low. Colorectal cancer is now the leading... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.